(Alliance News) - Omega Diagnostics Group PLC on Monday announced that its Visitect CD4 Advanced Disease test will be included in the Global Fund procurement list.
Shares in Omega Diagnostics were up 4.4% at 12.00 pence in London in midday trading.
The Global Fund is a financing and partnership organisation aimed at ending epidemics of AIDS, tuberculosis and malaria. It invests over USD4 billion per year.
As a result of Visitect CD4's inclusion, organisations with access to the Global Fund or UNITAID funds will be able to procure the HIV test after a review of procurement requests and an issue of a no-objection letter from the Global Fund.
This inclusion follows an assessment review by the Expert Review Panel for Diagnostics.
Omega is required to submit the Visitect CD4 test for World Health Organisation prequalification review in order to be prequalified before the end of the ERPD-authorised period. This period runs to September 2020.
The medical diagnostics firm confirmed it has already submitted Visitect CD4 to the World Health Organisation prequalification review process.
Omega Chief Executive Colin King said: "I am delighted that we have received this response from ERPD that allows procurement access to our Visitect CD4 Advanced Disease test in certain circumstances and we look forward to providing a unique test to organisations which can help improve the health outcomes of many people living with HIV."